Merck KGaA to Acquire Bio-Techne for $11 Billion
Merck KGaA (MRK) announced the acquisition of U.S. lab-tools supplier Bio-Techne for $11 billion in cash, or $73 per share, representing a 24% premium to Wednesday's close. The deal is expected to close in the first half of 2026.
Key Numbers
Germany's Merck KGaA (MRK) announced today its acquisition of Bio-Techne, a U.S. supplier of laboratory tools, in an all-cash deal valued at $11 billion. The acquisition aims to strengthen Merck's position in the life sciences and diagnostics sectors.
Deal Details
| Item | Value |
|---|---|
| Deal value | $11 billion |
| Price per share | $73 cash |
| Premium to close | 24% |
| Payment method | All cash |
| Expected close | H1 2026 |
Rationale
Merck seeks to expand its portfolio in lab tools and life sciences, particularly in protein and gene analysis tools, a fast-growing segment. Bio-Techne's offerings complement Merck's existing diagnostics and research solutions.
Regulatory Challenges
The deal is subject to regulatory approvals in the U.S. and Europe. Antitrust scrutiny is expected but analysts foresee no major hurdles due to limited product overlap.
Impact on Stocks
Bio-Techne shares are expected to rise near the 24% premium at market open. Merck's stock may face slight pressure due to the cash outlay, but the move is viewed as strategically positive long-term.
Frequently Asked Questions
Found this useful? Share it